result improv organ
growth outlook us move neutral
quarter improv outlook upgrad neutral
pr pr solut digit media
report adj ep ep beat consensus/our est
primarili better revenu slightli lower tax rate despit higher
cost overal good quarter solid organ growth across busi
tailwind backdrop given improv organ growth outlook came
sooner expect upgrad rate neutral under-perform
though see moder upsid near term given limit margin expans
elev leverag
better revenu lower tax rate despit higher exp
revenu increas better expect y/i
q/q org y/i ex fx/acquisit driven y/i q/q mt
came higher expect y/i q/q y/i ex fx/acquisit
led mute op leverag adj op margin bp y/i adj tax
rate lower end rang management paid debt gross leverag
fell vs target buyback increas q/q compani lower
expens guidanc in-lin expect
primarili due sale pr busi segment also re-align
improv org growth outlook margin/lev constraint
view organ revenu outlook improv earlier expect particularli
non-transact segment expect q/q moder transact
revenu lower volum still see growth y/i addit expect organ
growth non-transact segment within rang despit q/q
moder expect market data elev audit index elev aum/volum
expect adj expens around mid-point new lower
exp guidanc pr sale expect limit oper leverag
tax rate rang sale pr april management use
proce buy back stock lower share count continu
focu de-lever via debt paydown divi growth inv longer term
maintain estim move po upgrad neutral
given result guidanc outlook maintain rais
po base price-to-earnings given improv
organ growth outlook upgrad rate neutral under-perform
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
invest
nasdaq omx group found
lead diversifi global exchang offer
trade clear servic market data
product technolog product servic
financi index product list servic public
compani servic compani own
oper market clearinghous
central secur depositori across
europ list compani
global grown year
organ via acquisit
given improv organ growth outlook
came sooner expect yet limit margin
expans elev leverag potenti
area regulatori chang believ
share trade in-lin group
price object po base target pe multipl
ep premium recent histor averag given increas
portion recur revenu deriv po consid three primari factor
exchang revenu mix growth expect competition/barri
entri price manag abil manag margin cash flow well
strategi also look regulatori environ macro backdrop earn
volatil risk factor believ share trade in-lin
group given improv organ growth outlook yet limit margin expans
elev leverag expect hit leverag target till potenti
area regulatori chang
upsid risk po weak macro backdrop reduc competit less price
pressur margin technolog oper accret regulatori legal
downsid risk po lower volum outlook higher price pressur lower non-
transact revenu lower margin failur opportun
michael carrier cfa herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
new york mellon
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
